AI Article Synopsis
- The study aimed to determine if platelet transfusions could lower the risk of death or long-term disability in patients who experience intracerebral hemorrhage while on antiplatelet therapy.
- Conducted as a randomized, open-label phase 3 trial, this research compared outcomes between patients receiving platelet transfusions in addition to standard medical care and those receiving standard care alone.
- The findings could help inform treatment strategies for acute strokes linked to spontaneous bleeding in patients taking antiplatelets, addressing a significant clinical question regarding optimal post-hemorrhage care.
Article Abstract
Clinical questionIn patients taking antiplatelet therapy, does a platelet transfusion after acute spontaneous primary intracerebral hemorrhage reduce the risk of death or dependence?Article chosenBaharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral hemorrhage associated with antiplatelet therapy (PATCH): a randomized, open-label, phase 3 trial. Lancet 2016;387(10038):2605-13.Study objectiveThe primary objective of this study was to investigate whether a platelet transfusion with standard care, compared with standard care alone, reduced death or dependence after intracerebral hemorrhage associated with antiplatelet therapy use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/cem.2017.438 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!